

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
13 October 2022 (13.10.2022)



(10) International Publication Number
WO 2022/216184 A1

(51) International Patent Classification:

A61K 31/282 (2006.01) A61K 45/06 (2006.01)
A61K 31/337 (2006.01) A61P 35/00 (2006.01)
A61K 39/395 (2006.01)

TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(21) International Application Number:

PCT/RU2022/050122

(22) International Filing Date:

08 April 2022 (08.04.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

2021109765 08 April 2021 (08.04.2021) RU

(71) Applicant: JOINT STOCK COMPANY "BIOCAD"

[RU/RU]; pomeshch. 89, str. 1, d. 38, ul. Svyazi, the Settlement of Strelna, Intracity Municipality the Settlement of Strelna, Saint Petersburg, 198515 (RU).

(84) Designated States (unless otherwise indicated, for every kind of regional protection available):

ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to the identity of the inventor (Rule 4.17(i))
- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))
- of inventorship (Rule 4.17(iv))

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(72) Inventors: SHUSTOVA, Mariia Stanislavovna; ul. Frunze, d. 16, kv. 104, Saint Petersburg, 196135 (RU).

FOGT, Sergei Nikolaevich; Bogatyrskiy pr-kt, d. 28A, kv. 162, Saint Petersburg, 197372 (RU). KRYUKOV, Fedor Borisovich; Rybatskiy pr-kt, d. 15, korp.1, lit. A, kv. 221, Saint Petersburg, 192076 (RU). MOROZOV, Dmitry Valentinovich; Admiraltejskiy r-n, ul. Pochtamskaja, d. 20, kv. 3, Saint Petersburg, 190000 (RU).

(74) Agent: KONOVALOVA, Ksenia Dmitrievna; pomeshch. 89, str. 1, d. 38, ul. Svyazi, the Settlement of Strelna, Intracity Municipality the Settlement of Strelna, JSC "BIOCAD", Saint Petersburg, 198515 (RU).

(81) Designated States (unless otherwise indicated, for every kind of national protection available):

AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM,

(54) Title: MALIGNANT NEOPLASIS TREATMENT USING PD-1 ANTIBODY COMBINATION

(57) Abstract: The present invention relates to the use of antibody to PD-1, in particular prolgolimab, in combination with at least one chemotherapeutic agent, in particular paclitaxel, carboplatin or cisplatin, for treating a malignant neoplasm in a subject in need thereof, and to the use of the antibody to PD-1 prolgolimab in combination with antibody to VEGF, in particular bevacizumab, and at least one chemotherapeutic agent, in particular paclitaxel, carboplatin, or cisplatin, for treating a malignant neoplasm in a subject in need thereof. The present invention further relates to a method for treating a malignant neoplasm in a subject in need thereof, comprising administering a therapeutically effective amount of antibody to PD-1, in particular prolgolimab, in combination with at least one chemotherapeutic agent, in particular paclitaxel, carboplatin or cisplatin, and to a method for treating a malignant neoplasm in a subject in need thereof, comprising administering a therapeutically effective amount of the antibody to PD-1 prolgolimab in combination with antibody to VEGF, in particular bevacizumab, and at least one chemotherapeutic agent, in particular paclitaxel, carboplatin or cisplatin.



WO 2022/216184 A1